Red Book®

Pediatric Infectious Diseases Clinical Decision Support Chart
2. Auflage 2021
ISBN: 978-1-61002-508-9
Verlag: American Academy of Pediatrics

Buch, Englisch, 38 Seiten, Spiral bound, Format (B × H): 216 mm x 279 mm

Fully revised and updated, the second edition of this full-color chart collects many of the most clinically useful tables, algorithms, and other items from the Red Book and presents them in an enlarged, enhanced, colorized format that is lightweight, portable and easy to navigate.

Additionally, new tables have been created exclusively for this chart, synthesizing important clinical information from the Red Book text.

Autoren/Hrsg.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Infektionskrankheiten
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Pädiatrie, Neonatologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pflege Kinderkrankenpflege

Inhaltsverzeichnis

- 1. Staphylococcal Infections
- 2. Streptococcal Infections
- 3. Diarrheal Infections
- 4. Immunizations (runs for 2 spreads)
- 5. Antibiotic Prophylaxis
- 6. Immune Globulin (runs for 2 spreads)
- 7. Kawasaki Disease
- 8. Tuberculosis
- 9. Lyme Disease
- 10. Varicella-Zoster
- 11. Zika
- 12. Fungal Infections
- 13. Genital and Neonatal Herpes
- 14. Syphilis
- 15. HIV
- 16. Immunocompromised Children and Adolescents

Über Autor(innen)

David W. Kimberlin, MD, FAAP is the Editor of the 2021 AAP Report of the Committee on Infectious Diseases (Red Book). He also was Editor of the 2015 and 2018 editions and was an Associate Editor of the 2012 and 2009 editions and served on the AAP Committee on Infectious Diseases from 2005- 2011. Dr Kimberlin is the Sergio Stagno, MD. Endowed Chair in Infectious Diseases, Professor and Co-Division Director, Vice Chair for Clinical and Translational Research. His clinical and research interests include pediatric infectious diseases, antiviral therapeutics in rare diseases with a large unmet medical need, including neonatal herpes simplex virus (HSV) infections, congenital cytomegalovirus (CMV) disease, congenital Zika infection, neonatal and infantile influenza infection, and neonatal enteroviral sepsis syndrome.